杜瓦卢马布
医学
放化疗
内科学
肺癌
肿瘤科
CD8型
无进展生存期
危险系数
肿瘤浸润淋巴细胞
癌症
免疫系统
胃肠病学
免疫疗法
化疗
无容量
免疫学
置信区间
作者
Masayuki Shirasawa,Tatsuya Yoshida,Tatsuya Imabayashi,Kae Okuma,Yuji Matsumoto,Ken Masuda,Yuki Shinno,Yusuke Okuma,Yasushi Goto,Hidehito Horinouchi,Takaaki Tsuchida,Noboru Yamamoto,Yuko Nakayama,Shun-ichi Watanabe,Noriko Motoi,Yuichiro Ohe
标识
DOI:10.1016/j.ejca.2021.11.013
摘要
Background Chemoradiotherapy (CRT) followed by durvalumab treatment improved prognosis in unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study aimed to evaluate whether the status of the immune-related tumour microenvironment (TME) at baseline associates with the efficacy. Methods This retrospective study evaluated immune-related TME factors, including programmed cell death ligand 1 (PD-L1) (clone: 22C3) expression on tumour cells and the density of CD8-positive tumour-infiltrating lymphocytes (TILs) at pre-CRT in patients with unresectable LA-NSCLC treated with CRT only (CRT alone group) and those treated with CRT followed by durvalumab (Durva group). Results A total of 551 patients were included (N = 113 in the Durva group). Progression-free survival (PFS) in the Durva group was significantly greater than that in the CRT alone group (not reached [NR] vs 12.9 months; p = 0.002). In the CRT alone group, neither PD-L1 expression nor TIL status affected PFS; in contrast, in the Durva group, high density of CD8-positive TILs (TILHigh ≥100/mm2) and PD-L1-positive expression (tumour proportion score ≥1%; PD-L1+) was significantly associated with longer PFS (TIL: NR vs 9.5 months; p = 0.002; and PD-L1: NR vs 7.7 months; p = 0.003). On the other hand, in patients with epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, there was no significant difference in PFS between the groups (Durva vs CRT alone: 9.9 months vs 14.0 months; p = 0.77). Conclusions PD-L1+ and TILHigh at baseline could be predictive markers of the efficacy of CRT followed by durvalumab.
科研通智能强力驱动
Strongly Powered by AbleSci AI